Search Results

Pharm Country

Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association’s 84th Scientific Sessions

Gan & Lee Pharmaceuticals announced the presentation of three abstracts featuring their investigational products at the American Diabetes Association’s 84th Scientific Sessions.

June 17, 2024

·

3 min read

Pharm Country

Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association’s 84th Scientific Sessions

Gan & Lee Pharmaceuticals announced the results of the Phase 1b/2a clinical study of the Company’s independently developed glucagon-like peptide-1 receptor agonist, GZR18 Injection, in an obese/overweight population in China, along with the results of two other innovative insulins’ preclinical studies in poster presentations at the American Diabetes Association’s（ADA’s）84th Scientific Sessions.

June 22, 2024

·

7 min read

Press Releases

ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults

November 11, 2024

·

5 min read

Press Releases

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)

December 18, 2024

·

4 min read

Press Releases

Gan & Lee Pharmaceuticals’ Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies

October 15, 2024

·

8 min read

Press Releases

Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks

November 12, 2024

·

4 min read

Press Releases

Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)

September 16, 2024

·

6 min read

Press Releases

Gan & Lee Pharmaceuticals’ Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

July 22, 2024

·

4 min read

Press Releases

Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline

February 11, 2025

·

5 min read

Drug Development

Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)

Gan & Lee Pharmaceuticals Co., Ltd. is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee insulin glargine (GL-GLA) to a reference biologic.

October 14, 2021

·

2 min read